Crucell is a biotechnology company specializing in vaccines and biopharmaceutical technologies. The firm, a subsidiary of Johnson & Johnson, is headquartered in Leiden, Netherlands.

Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February 2011 and as of October 2014 Crucell is changing its identity into Janssen. For Janssen, the acquisition of Crucell has provided a firm foothold in the increasingly important field of disease prevention.

Currently they are combating twelve major infectious diseases with their range of marketed vaccines in the paediatric, travel and endemic and respiratory fields.

Innovation is the drive force behind their strong research & development (R&D) pipeline, with promising products in pre-clinical and clinical development. Crucell product candidates include flu-mAb, and antibody product effective against a broad range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination-all produced on our unique PER.C6® human-cell technology.

Headquartered in Leiden, the Netherlands, Crucell currently employs 1400 people and has offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the UK the USA and Vietnam.